Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Hepatic Arterial Infusion Chemotherapy with Cisplatin Versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis

Version 1 : Received: 23 September 2021 / Approved: 24 September 2021 / Online: 24 September 2021 (12:38:25 CEST)

How to cite: Zaizen, Y.; Nakano, M.; Fukumori, K.; Yano, Y.; Takaki, K.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.; Nakazaki, M.; Kuromatsu, R.; Okamura, S.; Iwamoto, H.; Shimose, S.; Shirono, T.; Noda, Y.; Kamachi, N.; Koga, H.; Torimura, T. Hepatic Arterial Infusion Chemotherapy with Cisplatin Versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Preprints 2021, 2021090429 (doi: 10.20944/preprints202109.0429.v1). Zaizen, Y.; Nakano, M.; Fukumori, K.; Yano, Y.; Takaki, K.; Niizeki, T.; Kuwaki, K.; Fukahori, M.; Sakaue, T.; Yoshimura, S.; Nakazaki, M.; Kuromatsu, R.; Okamura, S.; Iwamoto, H.; Shimose, S.; Shirono, T.; Noda, Y.; Kamachi, N.; Koga, H.; Torimura, T. Hepatic Arterial Infusion Chemotherapy with Cisplatin Versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Preprints 2021, 2021090429 (doi: 10.20944/preprints202109.0429.v1).

Abstract

Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 348 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 97) or sorafenib (n = 251) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 13.9 vs. 12.7 months; p = 0.0989). To reduce confounding effects, 176 patients were selected using propensity score-matched analysis (n = 88 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 16.2 vs. 12.2 months; p = 0.0060). Following stratification according to the Child–Pugh classification, for both patients with class A (MST: 24.0 vs. 15.6 months; p = 0.0097) and class B (MST: 8.5 vs. 6.9 months; p = 0.0391), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC, regardless of the hepatic reserve.

Keywords

hepatocellular carcinoma; hepatic arterial infusion chemotherapy; cisplatin; sorafenib; multikinase inhibitors; risk factors; propensity score-matched analysis

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.